Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 3, 2026
- Faeth Therapeutics reported $174.8 million in cash, cash equivalents and marketable securities as of September 30, 2026 and $20.4 million net loss. FDA granted Fast Track designation to PIKTOR plus paclitaxel, while Phase 2 topline data are expected by year-end.
- 10-Q report · filed Nov 3, 2026
- Faeth Therapeutics, Inc. reported a $206.6 million net loss for the nine months ended September 30, 2026, driven largely by $133.0 million of acquired IPR&D expense, while $174.8 million in cash and marketable securities supports PIKTOR trials through topline data.
The audio replay and transcript follow the call.